Airain ltd boosted its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 197.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,224 shares of the medical equipment provider’s stock after buying an additional 68,483 shares during the period. Airain ltd owned 0.10% of MiMedx Group worth $1,545,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. State of Alaska Department of Revenue increased its stake in shares of MiMedx Group by 1.3% in the first quarter. State of Alaska Department of Revenue now owns 11,100 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 140 shares during the period. Victory Capital Management Inc. increased its stake in shares of MiMedx Group by 15.4% in the first quarter. Victory Capital Management Inc. now owns 14,616 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 1,952 shares during the period. Great Lakes Advisors LLC purchased a new stake in shares of MiMedx Group during the second quarter valued at about $163,000. Paradigm Asset Management Co. LLC purchased a new stake in shares of MiMedx Group during the second quarter valued at about $167,000. Finally, LS Investment Advisors LLC increased its stake in shares of MiMedx Group by 343.5% in the first quarter. LS Investment Advisors LLC now owns 18,611 shares of the medical equipment provider’s stock valued at $177,000 after buying an additional 14,415 shares during the period. Institutional investors and hedge funds own 60.30% of the company’s stock.

Shares of MiMedx Group, Inc (MDXG) opened at 16.27 on Friday. The firm has a market capitalization of $1.75 billion, a P/E ratio of 85.63 and a beta of 1.03. The stock has a 50 day moving average of $15.47 and a 200-day moving average of $12.82. MiMedx Group, Inc has a 52-week low of $7.09 and a 52-week high of $17.47.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.07 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.07. The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $74.22 million. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. MiMedx Group’s revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 EPS. Equities analysts expect that MiMedx Group, Inc will post $0.31 earnings per share for the current fiscal year.

MiMedx Group announced that its board has initiated a stock buyback program on Wednesday, July 26th that permits the company to repurchase $14.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 0.9% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/mimedx-group-inc-mdxg-position-increased-by-airain-ltd/1535769.html.

Several equities research analysts recently issued reports on MDXG shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $18.00 target price on shares of MiMedx Group in a research note on Sunday, August 20th. BidaskClub upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. Needham & Company LLC started coverage on shares of MiMedx Group in a research report on Thursday, August 3rd. They set a “buy” rating for the company. Lake Street Capital raised their price objective on shares of MiMedx Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Finally, First Analysis downgraded shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 price objective for the company. in a research report on Tuesday, May 23rd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $14.67.

In related news, insider William Charles Taylor sold 80,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $14.52, for a total transaction of $1,161,600.00. Following the sale, the insider now directly owns 547,424 shares in the company, valued at approximately $7,948,596.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.40% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.

Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG).

Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.